导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.71% | 1537/4773 |
| 近一周 | -2.07% | 1164/5462 |
| 近一月 | -3.63% | 1875/5421 |
| 近一季 | -7.55% | 2444/5209 |
| 近半年 | -0.79% | 1379/4920 |
| 近一年 | 6.58% | 1438/4366 |
| 近两年 | 48.07% | 1535/2954 |
| 近三年 | 20.35% | 1449/2253 |
| 成立以来 | 114.04% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.17% 1724/4961 |
12.79% 2119/5312 |
- - |
- - |
| 2025 | 20.03% 2155/4813 |
-0.42% 2245/3635 |
2.36% 1620/4076 |
14.82% 2868/4524 |
2.57% 908/4813 |
| 2024 | 4.65% 1869/3463 |
-1.12% 1181/2808 |
-2.39% 1184/3014 |
11.26% 2535/3129 |
-2.55% 2126/3463 |
| 2023 | -11.24% 1383/2656 |
3.26% 1229/2280 |
-4.84% 1302/2385 |
-3.98% 1030/2515 |
-5.93% 1563/2655 |
| 2022 | -12.92% 307/2207 |
-9.80% 348/1919 |
7.02% 548/2016 |
-9.49% 282/2113 |
-0.33% 1594/2208 |
| 2021 | 0.97% 698/1822 |
-1.09% 430/1255 |
4.86% 841/1330 |
-3.97% 673/1466 |
1.38% 951/1822 |
| 2020 | 42.75% 257/1250 |
-5.35% 411/1028 |
16.75% 416/1067 |
15.99% 181/1164 |
11.37% 547/1184 |
| 2019 | 43.86% 184/1092 |
23.48% 554/739 |
1.06% 138/788 |
6.68% 118/850 |
8.06% 361/918 |
| 2018 | -19.06% 154/834 |
- - |
-5.18% 97/631 |
-2.49% 287/660 |
-11.22% 266/682 |
| 2017 | 27.39% 87/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 万家沪深300指数增强C VS. 长安沪深300非周期A(740101) |